Elsevier LogoInfluenza

    ThisiscontentfromClinicalKey

    Community Acquired Pneumonia (Adult)

    Sign up for your free ClinicalKey trial today!  Your first step in getting the right answers when you need them.

    Start Free Trial
    Mar.10.2025

    Community-Acquired Pneumonia in Adults

    Synopsis

    Key Points

    • Community-acquired pneumonia is an acute infection of the pulmonary parenchyma that is not acquired in a hospital or other health care facility (patient neither hospitalized nor residing in a long-term care facility for at least 14 days before the onset of symptoms)
    • History and physical examination suggest diagnosis, which is confirmed with chest radiography
    • Testing for the causative agent (eg, blood and sputum cultures) is not necessary for patients able to be treated as outpatients unless it is likely that treatment or isolation procedures would change based on a suspected unusual pathogen
      • When infection with SARS-CoV-2 is suspected or probable, confirm the diagnosis. CDC and WHO recommend polymerase chain reaction as the standard for diagnosis; antigen testing is also widely available
    • Select site of care decisions (eg, outpatient, general hospital ward, ICU) on pneumonia severity level, Pneumonia Severity Index score, and CURB-65r1 score. Do not allow these scoring systems to supersede clinical judgment
    • Select empiric antibiotic therapy based on the site of care and likely pathogen. Start treatment promptly once diagnosis of pneumonia appears likely
    • Patients able to be treated as outpatients with no significant risk of drug-resistant Streptococcus pneumoniae should receive first line therapy with a macrolide or second line therapy with doxycycline
    • Treat hospitalized (general ward) patients with no significant risk of drug-resistant Streptococcus pneumoniae empirically with respiratory quinolone monotherapy; alternatives include a β-lactam plus a macrolide or a β-lactam plus doxycycline
    • First line treatment for patients in ICU is usually a combination therapy of β-lactam plus either azithromycin or a respiratory quinolone
    • Additional coverage is required in patients with suspected community-acquired MRSA or Pseudomonas species infections
    • Treat all hospitalized patients who test positive for influenza with oseltamivir, regardless of the duration of illness
    • Treatment of COVID-19 pneumonia includes infection control measures, routine supportive care, and medications that include antiviral, monoclonal antibody, immunomodulator, and corticosteroid drugs
    • Pneumococcal vaccination is indicated in patients aged 50 years or older and in patients aged 19 to 49 years with certain underlying medical conditions or other risk factorsr2; influenza vaccination is recommended for all adults without contraindicationsr3
    • CDC recommends updated vaccination against COVID-19 for all adults; ACIP (Advisory Committee on Immunization Practices) recommends RSV vaccination for all adults aged 75 years or older, and for adults 60–74 years of age with increased risk of severe RSV disease r4r5

    Urgent Action

    • In patients being admitted, start empiric antibiotic therapy as soon as possible in the emergency department r6
    • Admit patients presenting with acute respiratory failure and septic shock directly to the ICU r7

    Pitfalls

    • Lack of response to initial therapy may suggest unusual pathogens (eg, Legionella species, fungi, viruses), nosocomial infection, or an infectious complication (eg, empyema, postobstructive pneumonia, abscess)
    • False-negative chest radiograph findings may occur, especially in a dehydrated patient; the diagnosis should then primarily depend on history and physical examination findings
    • False-negative respiratory sample cultures can occur if obtained after antibiotic therapy has been started r8

    Terminology

    Clinical Clarification

    • Community-acquired pneumonia in adults is acute infection of the pulmonary parenchyma not acquired in a hospital or other health care facility (patient neither hospitalized nor residing in a long-term care facility for at least 14 days before the onset of symptoms) r6

    Classification

    • By cause r9
      • Typical
        • Classically caused by Streptococcus pneumoniae, but other pyogenic organisms may cause a similar presentation
        • Characterized both by cough that produces purulent sputum and by lobar consolidation
      • Atypical
        • Caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella species, and respiratory viruses
        • Characterized by dry cough and patchy infiltrates
    • By severity level (and site of care) r7
      • Determined by severity of illness scores in combination with clinical judgment and an assessment of the patient’s social support
        • Pneumonia that can be managed in an outpatient setting
        • Pneumonia that should be managed with inpatient admission (general ward)
        • Pneumonia that is severe and should be managed in the ICU
      • Severe community-acquired pneumonia (either major criteria or 3 or more minor criteria) r7
        • Major criteria
          • Need for mechanical ventilation
          • Septic shock with need for vasopressors
        • Minor criteria
          • Respiratory rate of 30 breaths per minute or more
          • Ratio of arterial PaO₂ (partial pressure of oxygen) to fraction of FiO₂ (inspired oxygen) 250 or less
          • Multilobar disease
          • Leukopenia (leukocyte count less than 4000 cells/μL)
          • Uremia (BUN level of 20 mg/dL or higher)
          • Confusion or disorientation
          • Hypothermia (core temperature lower than 36 °C)
          • Thrombocytopenia (platelet count less than 100,000 cells/μL)
          • Hypotension requiring aggressive fluid resuscitation

    Diagnosis

    Clinical Presentation

    History

    • Fever may be reported c1
    • Chills, sweating, and/or shivering c2c3c4
    • Chest pain with inspiration and coughing c5c6c7c8
    • Cough (productive or nonproductive) c9c10
    • Dyspnea c11
    • Fatigue c12
    • Myalgia c13

    Physical examination

    • General
      • Altered mental status may occur with severe pneumonia, especially in older patients c14c15
      • Fever (typically over 38.1 °C) c16
        • In COVID-19 pneumonia, although fever is typical, it may be low-grade or absent, even in hospitalized patients (especially if vaccinated) r10
      • Signs of respiratory distress
        • Cyanosis, if hypoxemic c17
        • Tachypnea is a suggestive sign c18c19
        • Clinicians should be aware of the COVID-19–related phenomenon of silent (or "happy") hypoxemia: absence of signs of respiratory distress may be misleading
      • Tachycardia occurs with fever and with severe disease c20
      • Other symptoms that may suggest COVID-19 infection
        • Upper respiratory tract symptoms (eg, rhinorrhea, sneezing, sore throat) may be present in up to 20% of symptomatic infections r11
        • Alteration in smell and/or taste is less common but highly suggestive r12
        • Gastrointestinal symptoms (eg, abdominal pain, nausea, vomiting, diarrhea) are present in 10% to 20% of symptomatic infections r10r11
    • Pulmonary
      • Respiratory splinting c21
      • Palpable fremitus c22
      • Dullness to percussion c23
      • Bronchial breath sounds or rales r7c24c25
      • Egophony c26
      • Whispered pectoriloquy c27

    Causes and Risk Factors

    Causes

    • Common pathogens r13r14
      • Streptococcus pneumoniae (pneumococcus) c28
      • Mycoplasma pneumoniaec29
      • Haemophilus influenzaec30
      • Chlamydia pneumoniaec31
      • Staphylococcus aureusc32
      • Legionella species c33
      • Gram-negative bacilli c34
      • MRSA c35
      • Pseudomonas aeruginosac36
      • Respiratory viruses c37
        • SARS-CoV-2 r15r16c38
        • Influenza A and B viruses c39c40
        • Parainfluenza virus c41
        • Respiratory syncytial virus c42
        • Adenoviruses c43
        • Rhinovirus c44

    Risk factors and/or associations

    Other risk factors/associations
    • Hospitalization and treatment with parenteral antibiotics in the preceding 90 days c45
      • MRSA, Pseudomonas aeruginosa, resistant gram-negative bacilli
        • Documented history of infection with these organisms
        • Previously regarded as health care–associated pneumonia, infection due to these bacteria is now considered within the spectrum of community-acquired pneumonia r7
    • Chronic obstructive pulmonary disease c46
      • Streptococcus pneumoniae
      • Haemophilus influenzae
      • Moraxella (Branhamella) catarrhalis
      • Legionella species
    • Bronchiectasis c47
      • Pseudomonasaeruginosa
      • Burkholderia cepacia
      • Staphylococcus aureus
    • Cystic fibrosis c48
      • Pseudomonas aeruginosa
        • Most common organism in adults
    • Diabetes c49
      • Staphylococcus aureus
      • Gram-negative organisms
    • Renal disease c50
      • Streptococcus pneumoniae
    • Early-stage HIV c51
      • Streptococcus pneumoniae
      • Haemophilus influenzae
      • Mycobacterium tuberculosis
    • Late-stage HIV
      • Pneumocystisjiroveci
      • Cryptococcus species
      • Histoplasma species
    • Medical conditions that result in aspiration of nasopharyngeal secretions, food, liquids, or gastric contents c52
    • Alcohol use disorder c53
      • Streptococcus pneumoniae
      • Klebsiella pneumoniae
      • Anaerobic bacteria
    • Asplenia c54c55
      • Encapsulated organisms
        • Streptococcus pneumoniae
        • Haemophilus influenzae
    • Sickle cell disease c56
      • Streptococcus pneumonia
      • Haemophilus influenzae
    • Poor dental hygiene c57
      • Anaerobic bacteria
    • Smoking c58
      • Streptococcus pneumonia
      • Haemophilus influenzae
      • Moraxella (Branhamella) catarrhalis
      • Legionella species
    • Travel history c59
      • Travel to area of known outbreak within 2 weeks before illness c60
        • Legionella species
      • Travel to the southwestern United States within 1 month before illness c61
        • Coccidioides species
    • Exposure to animals c62
      • Exposure to bats or soil enriched with bird droppings c63c64
        • Histoplasma capsulatum
      • Exposure to birds c65
        • Chlamydia psittaci
      • Exposure to rabbits c66
        • Francisella tularensis
      • Exposure to farm animals or parturient cats c67c68
        • Coxiella burnetii
    • Comorbid conditions that have been conclusively associated with increased risk for severe COVID-19 infection include the following (based on systematic review or meta-analysis): r17
      • Chronic kidney disease
      • Chronic liver disease, specifically the following:
        • Cirrhosis
        • Non-alcoholic fatty liver disease
        • Alcoholic liver disease
        • Autoimmune hepatitis
      • Chronic lung disease, specifically the following:
        • Bronchiectasis
        • Chronic obstructive pulmonary disease
        • Interstitial lung disease
        • Pulmonary embolism
        • Pulmonary hypertension
      • Cerebrovascular disease
      • Diabetes type 1 and type 2
      • Malignancy, particularly hematologic malignancies
      • Corticosteroid or other immunosuppressive medication use
      • Cystic fibrosis
      • Tuberculosis
      • Solid organ or blood stem cell transplantation
      • Pregnancy and recent pregnancy
      • Primary immunodeficiencies
      • Obesity (BMI of 30 kg/m² or higher)
      • Cardiac conditions (eg, heart failure, coronary artery disease, cardiomyopathy)
      • Smoking, current and former
      • Mental health disorders (mood disorders and schizophrenia spectrum disorders)
      • Dementia
      • Physical inactivity

    Diagnostic Procedures

    Primary diagnostic tools

    • History and physical examination alone may be sufficient to suggest the diagnosis r13c69
    • Chest radiography or other chest imaging demonstrating an infiltrate confirms the diagnosis r13
    • Testing to identify a causative agent is not routine for outpatients, except in certain circumstances r13
    • Testing to identify a causative agent (eg, polymerase chain reaction, blood cultures, sputum testing, pleural fluid testing, antigen testing, and/or cultures for fungi and tuberculosis, depending on history and clinical findings) is indicated if any of the following apply: r13
      • Infection with SARS-CoV-2 is suspected or probable
      • Severe pneumonia
      • Pleural effusion and/or a cavitary infiltrate
      • Specific comorbidities (eg, alcohol use disorder, liver disease, leukopenia, chronic lung disease, asplenia)
      • Identification of a suspected pathogen would significantly alter antibiotic choice
      • Failure of outpatient treatment
      • Epidemiologic considerations (eg, outbreaks of public health importance)
    • Pulse oximetry assesses hypoxemia r13c70
    • Other laboratory tests—including blood gases, CBC, C-reactive protein, and blood chemistries (including lactate)—may be useful in both determining degree of severity at presentation and managing hospitalized patients r13
    • For hospitalized patients, multiplex nucleic acid detection testing for influenza A and B and SARS-CoV-2 is recommended; collect 2 separate specimens if multiplex testing is unavailable r18
      • RSV (respiratory syncytial virus) testing may be considered for selected patients (eg, older adults, patients with congenital cardiac disease, chronic lung disease, immunocompromise)
    • Serum procalcitonin has been used to discriminate between infectious and noninfectious causes of pneumonia and between bacterial and viral causes. However, current guidelines do not recommend its use either to determine need for antibacterial therapy or to determine when to discontinue antibiotics r7r19

    Laboratory

    • Blood gas tests are not routine but are indicated when there is respiratory distress and/or suspicion of carbon dioxide retention c71c72
      • PaO₂ or FiO₂ ratio less than 250 suggests the need for ICU admission and/or mechanical ventilation r20
    • CBC will reveal leukocytosis in most cases of community-acquired pneumonia c73
      • Leukopenia (WBC count less than 4000) suggests immunosuppression or severe infection and the need for hospitalization r20
      • Thrombocytopenia (platelet count less than 100,000 cells/mm³) may be present and is associated with poor prognosis r13
    • Serum chemistry testing is indicated for hospitalized patients receiving IV fluids and to monitor renal function and glucose levels in patients with severe pneumonia. BUN level can be used as a criterion to determine a CURB-65 score, and lactate levelr22 can be used to identify and manage sepsis r21c74
    • C-reactive protein c75
      • C-reactive protein level greater than 30 mg/L, in addition to suggestive symptoms and signs, implies diagnosis of pneumonia r19
    • Etiologic testing
      • Blood cultures are indicated for patients with the following: r7
        • Severe community-acquired pneumonia (patients admitted to ICU) c76
        • Patients being empirically treated for MRSA or Pseudomonas aeruginosa (or other resistant gram-negative bacilli)
        • Patients previously infected with MRSA or Pseudomonas aeruginosa (or other resistant gram-negative bacilli), especially those with history of respiratory tract infection
        • Patients who were hospitalized and received parenteral antibiotics, whether during the hospitalization event or not, in the last 90 days
      • Sputum Gram stain and culture are indicated for the following: r7
        • All ICU patients (severe) c77c78
          • Use an endotracheal specimen in intubated patients
        • Patients being empirically treated for MRSA or Pseudomonas aeruginosa (or other resistant gram-negative bacilli)
        • Patients previously infected with MRSA or Pseudomonas aeruginosa (or other resistant gram-negative bacilli), especially those with prior respiratory tract infection
        • Patients who were hospitalized and received parenteral antibiotics, whether during the hospitalization event or not, within the last 90 days
    • Pathogen-specific tests
      • SARS-CoV-2 polymerase chain reaction or antigen test c79
        • Polymerase chain reaction is regarded as the gold standard test for diagnosis r23r24
        • In general, polymerase chain reaction is more sensitive than antigen testing, although specificity is nearly equivalent r25
          • A negative antigen test result may warrant retesting (preferably within 2 days) with polymerase chain reaction if there is a high suspicion for infection based on clinical or epidemiologic indicators
        • Nasopharyngeal, deep nasal (midturbinate), anterior nare, oropharyngeal, or saliva specimens may be submitted for polymerase chain reaction testing; nasopharyngeal wash (or aspirate) or nasal aspirate specimens (using 1-1.5 mL of nonbacteriostatic saline) are also acceptable r26
        • Bronchoalveolar lavage or tracheal aspirate are suitable lower respiratory tract specimens for polymerase chain reaction testing. A deep cough sputum specimen is also acceptable (sputum induction not advised) r26
        • Antigen tests are validated only for use on certain specimens; check manufacturer's specifications
      • Legionella urinary antigen test
        • Indicated for patients with either of the following: r7
          • Severe community-acquired pneumonia c80
          • In cases where indicated by epidemiologic factors (eg, association with a Legionella outbreak, recent travel)
      • Pneumococcal urinary antigen test (for diagnosis of Streptococcus pneumoniae)
        • Indicated only for patients with severe community-acquired pneumonia r7
      • Influenza test r7
        • Obtain nasal swab samples to test for influenza in patients with suspected viral pneumonia r27c81c82
        • Testing for influenza with a rapid influenza molecular assay (ie, influenza nucleic acid amplification test) is preferred over a rapid influenza diagnostic test (ie, antigen test) r7
        • Standard polymerase chain reaction may be used if rapid molecular test is not available. It detects influenza A and B viruses on sputum and endotracheal or bronchoalveolar lavage specimens and confirms positive nasal swab rapid test result in nonepidemic settings r28c83c84
      • Respiratory syncytial virus
        • Consider testing for selected patients (eg, older adults, patients with congenital cardiac disease, chronic lung disease, immunocompromise)
        • Real-time reverse transcription-polymerase chain reaction is preferred test and may be performed on upper or lower respiratory tract specimens
      • Fungal culture and tuberculosis testing
        • Indicated for patients with the following:
          • Cavitary infiltrate on chest radiograph r13c85c86
          • Persistent cough associated with weight loss, weakness, or night sweats r27c87c88
          • Presence of risk factors for tuberculosis (eg, older adults, those who traveled to or reside in tuberculosis-endemic regions, those with low socioeconomic status) r27c89c90c91c92c93c94
      • Serology and/or polymerase chain reaction test may be indicated to confirm the diagnosis of pathogens such as Chlamydia, Legionella, or Mycoplasma pneumoniaer27c95c96c97c98c99c100

    Imaging

    • Chest radiography r13c101
      • Routine investigation for evaluation of pneumonia in adults
      • Results may be negative, especially with dehydration
      • Lung infiltrate is the hallmark finding
      • May demonstrate alveolar filling with inflammatory exudate or interstitial thickening
      • Pleural effusion may be present
      • With COVID-19, usually shows bilateral involvement, varying from consolidation in more severely ill patients to ground-glass opacities in less severe cases
    • Lung ultrasonography r29r30c102
      • Accurate alternative to chest radiography that may be performed at bedside in emergency department setting or in critically ill patients r31r32
      • May be used as adjunctive means of diagnosing pneumonia, especially in patients with baseline chest radiograph abnormalities
    • CT r32c103
      • More sensitive than plain radiographs for detecting pneumonia
      • Consider if clinical suspicion for pneumonia remains high despite negative chest radiography findings
      • Better at visualizing upper lobes and lingula, necrotizing infection, multilobar disease, interstitial infiltrates due to atypical pathogens, empyema, and pleural involvement
      • Useful for excluding tuberculosis or lung cancer
      • Can help differentiate COVID-19 pneumonia from other viral pneumonias r15

    Procedures

    Diagnostic thoracentesis r13c104
    General explanation
    • Insertion of a small-gauge needle between the ribs, through the thorax, and into the pleural space to access pleural fluid for diagnostic purposes
    • Procedure can be performed with or without ultrasonographic guidance
    Indication
    • Pleural effusions greater than 5 cm high on a lateral view chest radiograph c105
    Contraindications
    • No absolute contraindications
    • Relative
      • Uncorrected coagulopathy
      • Small effusion with secure clinical diagnosis
      • Mechanically ventilated patient
      • Perform bilateral thoracentesis only after ensuring absence of pneumothorax in the first side
    Complications r33
    • Pain at puncture site
    • Bleeding (eg, hematoma, hemothorax, hemoperitoneum)
    • Pneumothorax
    • Re-expansion pulmonary edema
    • Infection (eg, empyema, soft tissue infection)
    • Spleen or liver puncture
    • Vasovagal events
    • Retained intrapleural catheter fragments
    Interpretation of results
    • Pleural fluid analysis
      • Obtain pH, glucose, Gram stain, and aerobic and anaerobic cultures r34
        • Parapneumonic effusion and empyema are exudative
          • Protein level higher than 3 g/dL
          • Ratio of pleural fluid protein to serum protein greater than 0.5
          • Lactate dehydrogenase level higher than 200 units/L
          • Ratio of pleural fluid lactate dehydrogenase to serum lactate dehydrogenase higher than 0.6
          • Glucose level lower than 60 mg/mL
        • pH is generally low
        • WBC count may exceed 50,000 cells/mm³ with neutrophils predominating
      • Fluid can be saved for further analysis based on initial results
      • Other pleural fluid testing (eg, cytology) based on clinical suspicion

    Differential Diagnosis

    Most common

    • Bronchitis c106d1
      • Presents with fever, malaise, productive cough, hoarseness, chest pain, and muscle pain
      • Differentiated by chest radiography and physical examination
        • No radiographic evidence of pulmonary pathology
        • Signs of consolidation (eg, rales, egophony, fremitus) indicative of pneumonia will be absent
    • Seasonal influenza c107d2
      • Sudden onset of high fever with chills, myalgia, or malaise
      • Dry cough, sneezing, sore throat, nasal discharge, and substernal soreness
      • History of contact with an infected person
      • Viral infection present in the winter season
      • Differentiated by history and laboratory testing
        • Antigen detection test using nasopharyngeal secretion will help in detecting type A and type B viral antigens
    • Asthma d3
      • Patient may present with recurrent attacks of dyspnea with wheezing or accessory muscle use c108
      • Differentiated by history (absence of fever), chest radiography, spirometry or pulmonary function testing, and response to bronchodilators
    • Chronic obstructive pulmonary disease c109d4
      • Patients present with dyspnea, pursed lip breathing, or use of accessory muscles for breathing
      • Other features include chronic productive cough, cyanosis, tachycardia, and tachypnea
      • Differentiated by history, chest radiography, and spirometry or pulmonary function testing
        • Spirometry shows abnormal diffusing capacity, fixed reduction in FEV1, and increased total lung capacity and/or residual volume in patients with chronic obstructive pulmonary disease
        • Chest radiography shows hyperinflation with flattened diaphragm, tenting of the diaphragm at the rib, and increased retrosternal chest space in patients with chronic obstructive pulmonary disease
    • Congestive heart failure d5
      • Characterized by the following: c110
        • Dyspnea
        • Fatigue
        • Exercise intolerance
        • Fluid retention
      • Differentiated by the following:
        • Chest radiography showing the following:
          • Pulmonary edema
          • Pleural effusion
          • Pulmonary venous congestion
          • Chamber dilation
          • Kerley B lines
          • Cardiomegaly
        • Echocardiography showing abnormalities with cardiac structure and function
    • Pneumothorax
      • Sudden onset of breathlessness and chest pain c111
      • Differentiated by history, physical examination, and chest radiography
        • Chest radiography will reveal air in the pleural space
    • Pulmonary embolism d6
      • Blocking of pulmonary artery by thrombus
      • Patients present with dyspnea and pleuritic chest pain but usually do not have a fever or cough productive of purulent sputum c112
      • Calf tenderness and swelling may be present if embolism was caused by deep venous thrombosis
      • Differentiated by history, physical examination, and imaging
        • Chest CT shows filling defects in the pulmonary arteries
    • Tuberculosis d7
      • Patients present with weight loss, night sweats, and cough c113
      • Travel to or residence in a tuberculosis-infected endemic area or advanced age (born early 20th century during worldwide endemicity)
      • Differentiated by history, laboratory testing, and imaging
        • Positive tuberculin test result
        • Chest radiography findings of reactivation disease (usually in older patients) showing upper-lobe predominance or cavity, and/or granuloma formation
        • Chest radiography of primary tuberculous pneumonia (usually in in younger patients) showing hilar adenopathy, and/or pleural effusion (sometimes massive)

    Treatment

    Goals

    • Eradicate infection
    • Relieve symptoms and provide supportive care as needed
    • Prevent disease progression and complications

    Disposition

    Admission criteria

    Use severity of illness scores combined with clinical judgment to determine if patient can be safely managed as outpatient or should be managed as inpatient. 2019 guidelines recommend Pneumonia Severity Index preferentially over CURB-65 criteria r7

    • Pneumonia Severity Index r35
      • Uses a point system of several variables, including patient age, vital signs, mental status, and the presence of comorbid conditions (eg, neoplastic disease, liver disease, chronic heart failure, cerebrovascular disease, renal disease)
      • Classifies patients into a mortality risk level
        • Class I and II patients (fewer than 70 points) may be treated as outpatients
        • Class III patients should be treated in an observation unit or briefly hospitalized (71-90 points)
        • Class IV (91-130 points) and V (greater than 130 points) should be treated as inpatients
    • CURB-65 criteria r1
      • Patients receive 1 point for each of the following indicators:
        • Confusion (compared to baseline)
        • BUN greater than 19 mg/dL (urea greater than 7 mmol/l)
        • Respiratory rate at least 30 breaths per minute
        • Systolic blood pressure less than 90 mm Hg or diastolic blood pressure of 60 mm Hg or less
        • Age 65 years or older
      • Inpatient admission is recommended for patients with a score of 2 or more
      • Most patients with a score of 1 can be managed as outpatients; consider overnight observation for some patients
    • Studies of specific biomarkers used to identify high-risk patients have not proven more accurate than these scoring systems r36

    For COVID-19 pneumonia

    • Nonsevere pneumonia: admission criteria include radiographic evidence of pneumonia, progressive clinical illness, risk factors for severe disease, and inadequate care at home. CDC provides further guidance r37
    • More severe or critical respiratory tract disease requires ICU admission r38
    • Follow recommended infection prevention and control practices r39

    Consider inpatient admission for patients otherwise meeting criteria for outpatient treatment but who are unable to safely and reliably take medication orally or who have insufficient personal support r27

    Criteria for ICU admission
    • Recommended with either major criteria or 3 or more minor criteria (severe community-acquired pneumonia) r7
      • Major criteria
        • Need for mechanical ventilation
        • Septic shock with need for vasopressors
      • Minor criteria
        • Respiratory rate of 30 breaths per minute or more
        • Ratio of arterial PaO₂ to FiO₂ (fraction of inspired oxygen) of 250 or less
        • Multilobar disease
        • Leukopenia (leukocyte count less than 4000 cells/μL)
        • Uremia (BUN level of 20 mg/dL or higher)
        • Confusion or disorientation
        • Hypothermia (core temperature lower than 36 °C)
        • Thrombocytopenia (platelet count fewer than 100,000 cells/μL)
        • Hypotension requiring aggressive fluid resuscitation
    • Pneumonia prognostic prediction tools have also been used in practice to determine level of in-hospital care; ICU is appropriate in the following patients: r32
      • Pneumonia severity index: class V (greater than 130 points)
      • CURB-65r1 score of 4 or 5
    • For severe COVID-19 pneumonia
      • Admit patients with severe or critical respiratory tract disease to an intensive care environment r38
        • Tachypnea (respiratory rate greater than 30 breaths or less than 10 breaths per minute), severe respiratory distress, inadequate oxygenation (eg, SpO₂ less than 92%)
        • Presence of severe complications (eg, septic shock, acute respiratory distress syndrome)

    Recommendations for specialist referral

    • Refer to pulmonologist for the following:
      • Respiratory failure requiring noninvasive and positive pressure ventilation or intubation and mechanical ventilation
      • Worsening hypoxemia
      • Pleural effusion requiring chest tube drainage
      • Nonresolving pneumonia (characterized by persistent fever and absence of clinical improvement)
      • Bronchoscopic sampling, if necessary
    • Refer to infectious disease specialist for assistance with identification of causative agent and antibiotic management of severe pneumonia or pneumonia that does not respond to empiric antibiotics

    Treatment Options

    Determine the optimal care setting using severity of illness scores and clinical judgment r7

    For COVID-19 pneumonia d8

    • Until a diagnosis of COVID-19 is confirmed by polymerase chain reaction or antigen test, administer appropriate antimicrobial therapy for other viral pathogens (eg, influenza virus) or bacterial pathogens in accordance with severity of clinical disease, site of acquisition (hospital or community), epidemiologic risk factors, and local antimicrobial susceptibility patterns r18r24
    • WHOr24, NIHr40r18, and Surviving Sepsis Campaignr41 provide specific guidance for management of COVID-19
    • Current standard treatment options include infection control measures, routine supportive care, and medications including antivirals, monoclonal antibodies, immunomodulators, corticosteroids, and, for selected patients, therapeutic or prophylactic anticoagulation r40d8
    • Antivirals and monoclonal antibodies directed at viral components are most effective when used early in the course of infection (to prevent cell entry and viral replication); antiinflammatory drugs (eg, dexamethasone) and immunomodulators are of most benefit during the hyperinflammatory response in later phases of severe disease

    For non–COVID-19 pneumonias: begin empiric therapy based on treatment setting; in patients admitted to the hospital, give first antimicrobial dose before patient leaves emergency department

    • Outpatient treatment
      • First line therapy for patients without comorbidities or risk factors for antibiotic-resistant pathogens includes amoxicillin or doxycycline or a macrolide (only in areas with pneumococcal resistance to macrolides less than 25%) r7
      • For outpatient adults with the following comorbidities, antibiotic options include combination therapy or monotherapy r7
        • Comorbidities include: r7
          • Chronic heart, lung, liver, or renal disease
          • Diabetes
          • Alcohol use disorder
          • Active malignancy
          • Asplenia
        • Combination therapy r7
          • Amoxicillin-clavulanate or a cephalosporin (eg, cefpodoxime, cefuroxime), and
          • Macrolide or doxycycline
        • Monotherapy r7
          • Respiratory fluoroquinolone
      • Start treatment with oral oseltamivir in patients with suspected or confirmed influenza as soon as possible, independent of duration of illness before diagnosis r7r42
    • General ward inpatient treatment (nonsevere community-acquired pneumonia without risk factors for MRSA, Pseudomonas aeruginosa, or resistant gram-negative bacilli) r7
      • Monotherapy with an appropriate respiratory fluoroquinolone, orr7r43
      • A β-lactam plus a macrolide may be used r7r43
        • Doxycycline may be used in place of a macrolide r7
      • A systematic review showed either monotherapy with a respiratory quinolone or combination therapy with a β-lactam plus a macrolide to be superior to β-lactam monotherapy in patients requiring hospitalization r44
      • Start treatment with oral or enterically administered oseltamivir for hospitalized patients with suspected or confirmed influenza as soon as possible, independent of duration of illness before diagnosis; because patients with influenza often have concurrent bacterial infection, administer recommended antibacterial antibiotics, pending culture results r7r42
      • 2019 guidelines recommend clinicians only cover empirically for MRSA or Pseudomonas aeruginosa in adults with community-acquired pneumonia if locally validated risk factors for either pathogen are present. Infectious Diseases Society of America guidelines do not recommend empiric coverage (pending culture results) for these organisms based on individual risk factors in patients with nonsevere pneumonia r7
        • Empiric treatment options for MRSA include vancomycin or linezolid r7
        • Empiric treatment options for Pseudomonas aeruginosa include piperacillin-tazobactam, cefepime, ceftazidime, aztreonam, meropenem, or imipenem r7
    • ICU inpatient treatment (severe community-acquired pneumonia without risk factors for MRSA or Pseudomonas aeruginosa) r7
      • β-Lactam plus a macrolide r7
      • Alternatively, a β-lactam plus a respiratory fluoroquinolone may be used r7
      • Start treatment with oral or enterically administered oseltamivir for patients with suspected or confirmed influenza, independent of duration of illness before diagnosis; because concurrent bacterial infection is common with influenza, administer recommended antibacterial antibiotics, pending culture results r7
      • 2019 American Thoracic Society and Infectious Diseases Society of America guidelines recommend clinicians only cover empirically for MRSA or Pseudomonas aeruginosa in adults with community-acquired pneumonia if locally validated risk factors for either pathogen are present. Absent these, clinicians may treat patients with severe pneumonia empirically for these pathogens if history of recent (90 days) hospitalization and parenteral antibiotic treatment or documented past infection with these pathogens. De-escalate antibiotics if indicated by culture results r7
        • Empiric treatment options for MRSA include vancomycin or linezolid r7
        • Empiric treatment options for Pseudomonas aeruginosa include: r7
          • Piperacillin-tazobactam
          • Cefepime
          • Ceftazidime
          • Aztreonam
          • Meropenem
          • Imipenem

    General considerations

    • 2019 guidelines recommend that duration of antibiotic therapy be guided by a validated measure of clinical stability. Continue antibiotic therapy until patient achieves stability and for at least 5 days r7
      • Indicators of clinical stability r45
        • Temperature of 37.8 °C or lower
        • Heart rate of 100 beats per minute or fewer
        • Respiratory rate of 24 breaths per minute or fewer
        • Systolic blood pressure of 90 mm Hg or higher
        • Arterial oxygen saturation of 90% or higher or PO₂ of 60 mm Hg or higher on room air
        • Ability to maintain oral intake
        • Normal mental status
    • Most patients will achieve clinical stability within the first 48 to 72 hours; thus, a total duration of therapy of 5 days should be appropriate for most patients r7r46
      • 2019 guidelines suggest duration of therapy for community-acquired pneumonia due to suspected or proven MRSA or Pseudomonas aeruginosa should be 7 days r7
      • Other pathogens or clinical circumstances may require a longer duration:
        • Initial therapy is not effective against identified pathogen r7
        • Staphylococcus aureus lobar pneumonia (2 weeks) r32
        • Staphylococcus aureus bacteremia (4 weeks, IV) r32
        • Mycoplasma pneumoniae or Chlamydia pneumoniae (10-14 days) r32
        • Legionella (14-21 days) r32
        • Complications caused by extrapulmonary infections (eg, meningitis, endocarditis) r7
    • If there is no improvement within 72 hours of initiation of the empiric treatment, there may be drug resistance, an unsuspected pathogen, or unrecognized complications (eg, endobronchial obstruction, empyema)
    • When culture and antibiotic susceptibility results are available, adjust antibiotics to specific, narrow-spectrum therapy r7
    • Treatment can be switched from IV to oral once hemodynamic stability and clinical improvement are seen r7
    • Use of adjunctive corticosteroids remains controversial and clinical studies have produced conflicting reports. They may be considered in some cases of severe pneumonia, particularly with septic shock r7r32r43
      • 2019 Infectious Diseases Society of America guidelines recommend not routinely using corticosteroids in adults with nonsevere community-acquired pneumonia and suggest not routinely using corticosteroids in adults with severe community-acquired pneumonia or severe influenza pneumonia r7
      • 2019 Infectious Diseases Society of America guidelines endorse the Surviving Sepsis Campaign recommendationsr47 on the use of steroids in patients with septic shock refractory to adequate fluid resuscitation and vasopressor support r7

    Drug therapy

    • Antibiotics r14
      • Macrolides c114
        • First line therapy for outpatient treatment; used in combination with other antibiotics in the inpatient setting
        • Azithromycin c115
          • Azithromycin Oral tablet; Outpatient Adults: 500 mg PO on day 1, followed by 250 mg PO once daily for at least 5 days.
          • Azithromycin Oral tablet; Hospitalized Adults: 500 mg PO once daily for at least 5 days.
          • Azithromycin Solution for injection; Adults: 500 mg IV once daily for at least 5 days.
        • Clarithromycin c116
          • Clarithromycin Oral tablet; Adults: 500 mg PO every 12 hours for at least 5 days.
      • Tetracyclines c117
        • Acceptable alternative to macrolides
        • Doxycycline c118
          • Doxycycline Hyclate Oral tablet; Adults: 100 mg PO every 12 hours for at least 5 days.
          • Doxycycline Hyclate Solution for injection; Adults: 100 mg IV every 12 hours for at least 5 days.
      • Quinolones c119
        • Respiratory quinolones (ie, gemifloxacin, moxifloxacin, levofloxacin, delafloxacin) are first line outpatient therapy for patients with community-acquired pneumonia who are at risk for multidrug-resistant Streptococcus pneumoniae
        • Gemifloxacin c120
          • Gemifloxacin Oral tablet; Adults: 320 mg PO once daily for at least 5 days.
        • Moxifloxacin c121
          • Moxifloxacin Hydrochloride Oral tablet; Adults: 400 mg PO once daily for at least 5 days.
          • Moxifloxacin Hydrochloride Solution for injection; Adults: 400 mg IV once daily for at least 5 days.
        • Levofloxacin c122c123
          • Levofloxacin Oral tablet; Adults: 750 mg PO every 24 hours for at least 5 days.
          • Levofloxacin Solution for injection; Adults: 750 mg IV every 24 hours for at least 5 days.
        • Delafloxacin c124
          • Delafloxacin Oral tablet; Adults: 450 mg PO every 12 hours for 5 to 10 days.
          • Delafloxacin Solution for injection; Adults: 300 mg IV every 12 hours for 5 to 10 days.
      • Penicillins c125c126
        • Frequently used in combination regimens in both outpatient and inpatient settings
        • Amoxicillin c127c128
          • Amoxicillin Trihydrate Oral tablet; Adults: 1 g PO every 8 hours for at least 5 days.
        • Amoxicillin-clavulanate c129c130
          • Amoxicillin Trihydrate, Clavulanate Potassium Oral tablet; Adults: 875 mg amoxicillin with 125 mg clavulanate PO every 12 hours or 500 mg amoxicillin with 125 mg clavulanate PO every 8 hours for at least 5 days.
          • Amoxicillin Trihydrate, Clavulanate Potassium Oral tablet, extended-release; Adults: 2,000 mg amoxicillin with 125 mg clavulanate PO every 12 hours for at least 5 days.
        • Ampicillin-sulbactam c131c132
          • Ampicillin Sodium, Sulbactam Sodium Solution for injection; Adults: 1.5 g (1 g ampicillin and 0.5 g sulbactam) or 3 g (2 g ampicillin and 1 g sulbactam) IV every 6 hours for at least 5 days.
        • Piperacillin-tazobactam c133c134
          • Piperacillin Sodium, Tazobactam Sodium Solution for injection; Adults: 4.5 g (4 g piperacillin and 0.5 g tazobactam) IV every 6 hours for at least 7 days.
      • Cephalosporins c135c136
        • Frequently used in combination regimens in both outpatient and inpatient settings
        • Cefuroxime c137c138
          • Cefuroxime Axetil Oral tablet; Adults: 500 mg PO every 12 hours for at least 5 days.
        • Cefpodoxime c139c140
          • Cefpodoxime Proxetil Oral tablet; Adults: 200 mg PO every 12 hours for at least 5 days.
        • Ceftriaxone c141c142
          • Ceftriaxone Sodium Solution for injection; Adults: 1 to 2 g IV every 24 hours for at least 5 days.
        • Cefotaxime c143c144
          • Cefotaxime Sodium Solution for injection; Adults: 1 to 2 g IV every 8 hours for at least 5 days.
        • Ceftaroline c145
          • Ceftaroline fosamil Solution for injection; Adults: 600 mg IV every 12 hours for at least 5 days.
        • Cefepime c146c147
          • Cefepime Hydrochloride Solution for injection; Adults: 2 g IV every 8 hours for at least 7 days.
        • Ceftazidime c148
          • Ceftazidime Sodium Solution for injection; Adults: 2 g IV every 8 hours for at least 7 days.
      • Carbapenems c149c150
        • Used in combination regimens in inpatient and ICU settings to manage seriously ill patients with community-acquired pneumonia; imipenem-cilastatin and meropenem also provide coverage for suspected Pseudomonas infection
        • Imipenem-cilastatin c151c152
          • Imipenem, Cilastatin Sodium Solution for injection; Adults: 500 mg IV every 6 hours for at least 7 days.
        • Meropenem c153c154
          • Meropenem Solution for injection; Adults: 1 g IV every 8 hours for at least 7 days.
      • Monobactams c155c156
        • Used in combination regimens in inpatient and ICU settings to manage seriously ill patients with community-acquired pneumonia who are allergic to penicillin
        • Aztreonam c157c158
          • Aztreonam Solution for injection; Adults: 2 g IV every 8 hours for at least 7 days.
      • Glycopeptides c159c160
        • Used for the treatment of MRSA and penicillin-resistant pneumococci
        • Vancomycin c161c162
          • Vancomycin Hydrochloride Solution for injection; Adults: 20 to 35 mg/kg/dose (Max: 3,000 mg/dose) IV loading dose, followed by 15 to 20 mg/kg/dose IV every 8 to 12 hours for at least 7 days; adjust dose based on target PK/PD parameter. Consider loading dose in critically ill patients.
      • Oxazolidinones c163c164
        • Used for treatment of infections due to aerobic gram-positive bacteria, including MRSA and penicillin-resistant pneumococci
        • Linezolid c165c166
          • Linezolid Oral tablet; Adults: 600 mg PO every 12 hours for at least 7 days.
          • Linezolid Solution for injection; Adults: 600 mg IV every 12 hours for at least 7 days.
      • Pleuromutilin c167
        • Lefamulin r48c168
          • First-in-class antibiotic approved to treat community-acquired pneumonia
          • Lefamulin Oral tablet; Adults: 600 mg PO every 12 hours for 5 days.
          • Lefamulin Solution for injection; Adults: 150 mg IV every 12 hours for 5 to 7 days.
    • Antiviral agent r14r42c169
      • Antiviral agents are recommended for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who are hospitalized; or who are at high risk for complications, regardless of time since symptom onset. Can be considered for previously healthy, symptomatic outpatients not at high risk for influenza complications if initiated within 48 hours of onset of symptoms c170c171
      • Neuraminidase inhibitors c172
        • Oseltamivir c173
          • Oseltamivir Phosphate Oral capsule; Adults: 75 mg PO twice daily for 5 days.

    Nondrug and supportive care

    Supplemental oxygen or mechanical ventilation r49

    • May be required in patients with severe pneumonia or underlying cardiopulmonary disease c174c175c176
    • Maintain oxygen saturation within 94% to 98% in patients with hypoxemia r43

    Respiratory therapy c177

    • Postural drainage facilitated by chest percussion may be helpful in patients who have difficulty mobilizing respiratory secretions c178c179

    Breathing exercises c180

    • Strengthen the chest wall muscles; beneficial particularly to sedentary patients
    • Help patients mobilize secretions to improve expectoration

    Venous thromboembolism prophylaxis r43c181

    • Low-molecular-weight heparin is recommended in patients at high risk
    • Early ambulation is recommended

    Smoking cessation r50c182

    • Advise patients to quit smoking, using counseling and pharmacologic approaches recommended in tobacco cessation guidelines and reviews r50r51d9
    Procedures
    Therapeutic thoracentesis c183
    General explanation
    • Drainage of pleural fluid for therapeutic (versus diagnostic) purposes
      • Relieves dyspnea caused by a large parapneumonic effusion
      • Evacuation of purulent fluid is essential for treatment of empyema
    Indication
    • Parapneumonic pleural effusion r13
      • Fluid more than 5 cm high on lateral view of an upright chest radiograph or more than 10 mm of fluid on lateral decubitus view
    • Pleural fluid drainage by chest tube is recommended in cases of empyema r52
      • Pleural fluid pH is less than 7.28
      • Pleural fluid glucose level is less than 40 mg/dL
      • Ratio of pleural fluid to serum glucose is less than 0.5
      • Pleural fluid lactate dehydrogenase level is greater than 1000 units/L
    Contraindications
    • No absolute contraindications
    • Relative
      • Uncorrected coagulopathy
      • Mechanically ventilated patient
      • Perform bilateral thoracentesis only after ensuring absence of pneumothorax in the first side
    Complications r33
    • Pain at puncture site
    • Bleeding (eg, hematoma, hemothorax, hemoperitoneum)
    • Pneumothorax
    • Re-expansion pulmonary edema
    • Infection (eg, empyema, soft tissue infection)
    • Spleen or liver puncture
    • Vasovagal events
    • Retained intrapleural catheter fragments

    Comorbidities

    • Patients with comorbid disorders such as neoplastic disease, liver disease, congestive heart failure, cerebrovascular disease, or renal disease are likely to require hospital admission and IV antibiotics, at least initially c184c185c186c187c188
    • Immunocompromised patients c189
      • Prone to multiorganism pneumonia, including unusual pathogens such as cytomegalovirus, Pneumocystis jiroveci, and fungal infection
      • Microbiologic diagnosis may require bronchoscopy with biopsy, immunohistology, and quantitative molecular assays
      • Begin empiric therapy as soon as possible based on epidemiologic history, sputum Gram stain, previous courses of antimicrobial agents, and historical microbiologic data
    • Pneumonia caused by SARS-CoV-2 is a prominent feature of COVID-19; clinicians must consider whether treatment for additional potential causes of community-acquired pneumonia is appropriate r16c190

    Special populations

    • Older patients
      • Classic signs and symptoms may be absent or altered in older patients
        • Presentation may include nonspecific symptoms such as confusion r27
      • May recover more slowly compared with younger patients
      • Aspiration is an important risk factor for community-acquired pneumonia in older patients
    • Pregnant patients
      • Prone to preterm labor and delivery
      • Prone to pulmonary edema
      • Acidosis and hypoxic state are poorly tolerated by the fetus
      • High risk for severe influenza
      • Treat with pregnancy-safe antibiotics
        • Azithromycin or erythromycin with or without ceftriaxone, depending on severity of illness; antiviral neuraminidase inhibitor for influenza
        • Antibiotics to be avoided in pregnancy include doxycycline, fluoroquinolones, and clarithromycin
        • Lefamulin may cause fetal harm when administered during pregnancy; effective contraception use is recommended for patients of reproductive potential

    Monitoring

    • 2019 guidelines recommend against routinely obtaining follow-up chest imaging in adults with community-acquired pneumonia whose symptoms have resolved within 5 to 7 days r7
    • In hospitalized patients with confirmed COVID-19, repeated testing may be done to document clearance of virus, defined as 2 consecutive negative results on polymerase chain reaction at least 24 hours apart r39

    Complications and Prognosis

    Complications

    • Reduction in breathing capacity requiring mechanical ventilation c191c192
    • Empyema or lung abscess secondary to inadequately treated pleural effusion c193
    • Systemic complications (eg, sepsis, meningitis, bacteremia, endocarditis) c194c195c196c197
    • Pneumonia may recur in recently treated patients, particularly in high-risk groups (eg, older patients, patients who smoke, patients who have alcohol use disorder, immunosuppressed patients, patients with bronchopulmonary anatomic abnormalities) c198c199c200c201c202

    Prognosis

    • Outcomes are improved through early diagnosis and timely administration of antibiotics r8r53
      • Treatment within 4 to 6 hours of hospital arrival reduces mortality
    • Patients with a CURB-65r1 score of 0 to 1 or a Pneumonia Severity Index risk class of I and II are at low risk of mortality. Mortality rate is higher in patients with higher scores or risk class
    • Infections due to Staphylococcusaureus or gram-negative bacilli and aspiration pneumonia are associated with high mortality rates for all populations
    • Incorrect diagnosis, comorbidities, inappropriate medication dose or route of administration, presence of an unusual or unanticipated pathogen, adverse drug reactions, or complications negatively affect prognosis
    • With COVID-19 pneumonia, patients who require hospital admission often require prolonged inpatient stay (more than 20 days) and experience significant deconditioning. Infection fatality ratio (proportion of deaths among all who are infected, including confirmed cases, undiagnosed cases, and unreported cases) varies across global locations but has been estimated as 0.15% r10r11r54

    Screening and Prevention

    Prevention

    • Tobacco use
      • Smoking cessation is important for preventing pneumonia, especially in older patients r55c203d9
    • Immunization d10
      • Pneumococcal vaccine c204
        • In the United States, 2 formulations have historically been available: PCV13 (13-valent pneumococcal conjugate vaccine) and PPSV23 (pneumococcal polysaccharide vaccine); in 2021, PCV20 (20-valent pneumococcal conjugate vaccine) and PCV15 (15-valent pneumococcal conjugate vaccine) were licensed by FDA for adults aged 18 years or older; in 2024, the ACIP recommended PCV21 (21-valent pneumococcal conjugate vaccine) as an option for adults aged 19 years or older who are currently recommended to receive PCV15 or PCV20 r56r57
        • ACIP recommends PCV15, PCV20, or PCV21 for adults aged 50 years or older who have not received pneumococcal conjugate vaccine and for adults aged 19 to 49 years with certain underlying conditions r2r56r57
          • Adults aged 50 years or older who have not previously received pneumococcal conjugate vaccine or whose earlier vaccination history is unknown should receive 1 dose of pneumococcal conjugate vaccine (PCV21, PCV20, or PCV15) r2r56
          • Adults aged 50 years or older who have an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak should receive 1 dose of PCV15, PCV20, or PCV21 r2r56
          • Adults aged 19 to 49 years with certain underlying medical conditions or other risk factors who have not previously received pneumococcal conjugate vaccine or whose earlier vaccination history is unknown should receive 1 dose of pneumococcal conjugate vaccine (PCV21, PCV20, or PCV15) r2r56
          • For both age groups (19 years and older), if PCV15 is used, it should be followed by a dose of PPSV23 at least 1 year later (a minimum interval of 8 weeks can be considered for adults who have an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak) r2r56
          • For adults who have previously received only PPSV23, pneumococcal conjugate vaccine (PCV21, PCV20, or PCV15) may be administered at least 1 year after their last PPSV23 dose r2r56
            • When PCV15 is used for those with the history of receiving PPSV23, it does not need to be followed by another dose of PPSV23 r57
          • For adults who only received PCV13, administer single dose of PCV21 or PCV20 at least 1 year following PCV13 r2r56
          • For adults who received PCV13 at any age and PPSV23 before age 65 years, administer PCV21 or PCV20 at least 5 years after the last pneumococcal vaccine r2r56
          • For adults who received PCV13 at any age and PPSV23 at age 65 years or older, use shared decision-making to determine administration of PCV21 or PCV20 at least 5 years since the last pneumococcal vaccine r2r56
          • For adults aged 19 to 49 years with immunocompromising condition, cochlear implant, or cerebrospinal fluid leak who received PCV13 and 1 dose of PPSV23, administer a single dose of PCV21 or PCV20 at least 5 years after the last pneumococcal vaccine r2r56
          • For adults aged 19 to 49 years with immunocompromising condition, cochlear implant, or cerebrospinal fluid leak who received PCV13 and 2 doses of PPSV23, pneumococcal vaccination recommendations should be reviewed again at age 50 years; alternatively, a single dose of either PCV21 or PCV20 can be administered at least 5 years after the last pneumococcal vaccine r2
          • For adults aged 19 to 49 years with chronic medical conditions who received PCV13 and 1 dose of PPSV23, pneumococcal vaccination recommendations should be reviewed again at age 50 years r2
        • ACIP considers the following to be underlying medical conditions or risk factors for adults in the 19- to 49-year age group: r2
          • Alcoholism; chronic heart, liver, or lung disease; chronic renal failure; cigarette smoking; cochlear implant; congenital or acquired asplenia; cerebrospinal fluid leak; diabetes mellitus; generalized malignancy; HIV; Hodgkin disease; immunodeficiency; iatrogenic immunosuppression; leukemia, lymphoma, or multiple myeloma; nephrotic syndrome; solid organ transplant; sickle cell disease; or other hemoglobinopathies r2
      • Influenza vaccination
        • Annual seasonal influenza vaccination is recommended for all adults without contraindications r3c205
      • COVID-19
        • CDC recommends vaccination with updated (2024–2025 formula) COVID-19 vaccine for all adults; refer to published administration schedules r4
      • RSV vaccine
        • 3 vaccines have been approved for prevention of RSV-associated lower respiratory tract disease in adults aged 60 years or older: an adjuvanted recombinant stabilized prefusion F protein vaccine (Arexvy), a recombinant stabilized prefusion F protein vaccine (Abrysvo), and an mRNA vaccine (mResvia) r5
        • ACIP recommends a single dose of FDA-approved RSV vaccine for all adults aged 75 years or older, and for adults 60 to 74 years of age with increased risk of severe RSV disease r5
    • Dental hygiene
      • Lack of good dental hygiene is a risk factor for community-acquired pneumonia; periodic dental hygiene checks are recommended c206
    MacFarlane J and Patel S: CURB-65 Score for Pneumonia Severity. MDCalc website. Accessed February 7, 2024. https://www.mdcalc.com/calc/324/curb-65-score-pneumonia-severityhttps://www.mdcalc.com/calc/324/curb-65-score-pneumonia-severityKobayashi M et al: Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 74(1):1-8, 202539773952Grohskopf LA et al: Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 influenza season. MMWR Recomm Rep. 73(5):1-25, 202439197095CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. CDC website. Updated October 31, 2024. Accessed March 6, 2025. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.htmlhttps://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.htmlBritton A et al: Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 73(32):696-702, 202439146277American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Community-Acquired Pneumonia et al: clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med. 77(1):e1-57, 202133349374Metlay JP et al: Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 200(7):e45-67, 201931573350Dunbar LM et al: High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 37(6):752-60, 200312955634Watkins RR et al: Diagnosis and management of community-acquired pneumonia in adults. Am Fam Physician. 83(11):1299-306, 201121661712Huang C et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395(10223):497-506, 202031986264Chen N et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. ePub, 202032007143Sudre CH et al: Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study. Lancet Digit Health. 3(9):e577-86, 202134305035Mandell LA et al: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 44(suppl 2):S27-72, 200717278083Metlay JP et al: Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America [online supplement]. AM J Respir Crit Care Med. 200(7):e45-67, 2019https://www.atsjournals.org/doi/suppl/10.1164/rccm.201908-1581STKao YS et al: A meta-analysis of computerized tomography-based radiomics for the diagnosis of COVID-19 and viral pneumonia. Diagnostics (Basel). 11(6):991, 202134072573Metlay JP et al: Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. Ann Intern Med. 173(4):304-5, 202032379883CDC: COVID-19: Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19: Information for Healthcare Providers. CDC website. Updated February 9, 2023. Accessed November 14, 2024. https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.htmlhttps://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.htmlCDC: Clinical Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses Are Co-circulating. CDC website. Updated December 6, 2023. Accessed February 7, 2024. https://www.cdc.gov/flu/hcp/clinical-guidance/testing-guidance-for-clinicians.htmlhttps://www.cdc.gov/flu/hcp/clinical-guidance/testing-guidance-for-clinicians.htmlHill AT et al: Adult outpatients with acute cough due to suspected pneumonia or influenza: CHEST guideline and expert panel report. Chest. 155(1):155-67, 201930296418Ho E: Community-acquired pneumonia in adults and children. Prim Care. 40(3):655-69, 201323958362Chalmers JD et al: Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia: systematic review and meta-analysis. Thorax. 65(10):878-83, 201020729231Levy MM et al: The Surviving Sepsis Campaign bundle: 2018 update. Crit Care Med. 46(6):997-1000, 201829767636CDC: COVID-19: Overview of Testing for SARS-CoV-2, the Virus That Causes COVID-19. CDC website. Updated January 9, 2024. Accessed November 14, 2024. https://archive.cdc.gov/#/details?url=https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.htmlhttps://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.htmlWHO: Living Guidance for Clinical Management of COVID-19. Version 7. WHO website. Updated August 18, 2023. Accessed February 7, 2024. https://app.magicapp.org/#/guideline/j1WBYnhttps://app.magicapp.org/#/guideline/j1WBYnCDC: Interim Guidance for Antigen Testing for SARS-CoV-2. CDC website. Updated May 11, 2023. Accessed February 7, 2024. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.htmlhttps://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.htmlCDC: COVID-19: Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. CDC website. Updated July 15, 2022. Accessed November 14, 2024. https://www.cdc.gov/covid/hcp/clinical-care/clinical-specimen-guidelines.htmlhttps://www.cdc.gov/covid/hcp/clinical-care/clinical-specimen-guidelines.htmlLim WS et al: BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 64(suppl 3):iii1-55, 200919783532Coutinho HD et al: Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers. Int Arch Med. 1(1):24, 200818992146Llamas-Álvarez AM et al: Accuracy of lung ultrasonography in the diagnosis of pneumonia in adults: systematic review and meta-analysis. Chest. 151(2):374-82, 201727818332Long L et al: Lung ultrasound for the diagnosis of pneumonia in adults: a meta-analysis. Medicine (Baltimore). 96(3):e5713, 201728099332Orso D et al: Lung ultrasound in diagnosing pneumonia in the emergency department: a systematic review and meta-analysis. Eur J Emerg Med. 25(5):312-21, 201829189351Rider AC et al: Community-acquired pneumonia. Emerg Med Clin North Am. 36(4):665-83, 201830296998Ault MJ et al: Thoracentesis outcomes: a 12-year experience. Thorax. 70(2):127-32, 201525378543Daly JS et al: Acute pneumonia. In: Bennett JE et al, eds: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:889-913.e6Ebell MH: Outpatient vs. inpatient treatment of community acquired pneumonia. Fam Pract Manag. 13(4):41-4, 200616671349Viasus D et al: Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. 72(3):273-82, 201626777314CDC: COVID-19: Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for Coronavirus Disease 2019 (COVID-19). CDC website. Updated February 12, 2020. Accessed February 7, 2024. https://stacks.cdc.gov/view/cdc/85034https://stacks.cdc.gov/view/cdc/85034WHO: Clinical Care of Severe Acute Respiratory Infections--Tool Kit: Interim Guidance. WHO website. Published April 11, 2020. Updated April 6, 2022. Accessed March 6, 2025. https://www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kithttps://www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kitCDC: COVID-19: Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. CDC website. Updated May 8, 2023. Accessed February 7, 2024. https://www.cdc.gov/covid/hcp/infection-control/https://www.cdc.gov/covid/hcp/infection-control/NIH. COVID-19 Treatment Guidelines. NIH website. Updated November 2, 2023. Accessed November 14, 2024. https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdfhttps://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdfAlhazzani W et al: Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 46(5):854-87, 202032222812CDC: Influenza Antiviral Medications: Summary for Clinicians. CDC website. Updated December 8, 2023. Accessed March 6, 2025. https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.htmlhttps://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.htmlLee MS et al: Guideline for antibiotic use in adults with community-acquired pneumonia. Infect Chemother. 50(2):160-98, 201829968985Lee JS et al: Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA. 315(6):593-602, 201626864413Halm EA et al: Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 279(18):1452-7, 19989600479Furukawa Y et al: Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. BMJ Open. 13(3):e061023, 202336948555Rhodes A et al: Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 43(3):304-77, 201728101605Nabriva Therapeutics: Xenleta (Lefamulin): Prescribing Information. Nabriva Therapeutics website. Updated June 2021. Accessed October 13, 2022.https://www.accessdata.fda.gov/scripts/cder/daf/index.cfmZhang Y et al: Oxygen therapy for pneumonia in adults. Cochrane Database Syst Rev. 3:CD006607, 201222419316Agency for Healthcare Research and Quality: Treating Tobacco Use and Dependence: 2008 Update. AHRQ website. Updated April 2013. Accessed March 6, 2025. https://www.ahrq.gov/prevention/guidelines/tobacco/clinicians/update/index.html#https://www.ahrq.gov/prevention/guidelines/tobacco/clinicians/update/index.html#Rigotti NA et al: Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 5:CD001837, 201222592676Sahn SA: Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis. 45(11):1480-6, 200717990232Meehan TP et al: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 278(23):2080-4, 19979403422Chu K et al: Evaluating risk stratification scoring systems to predict mortality in patients with COVID-19. BMJ Health Care Inform. 28(1):e100389, 202134521623Nuorti JP et al: Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 342(10):681-9, 200010706897Kobayashi M et al: Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 73(36):793-798, 202439264843Kobayashi M et al: Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 72(3):1-39, 202337669242
    Small Elsevier Logo

    Cookies are used by this site. To decline or learn more, visit our cookie notice.


    Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

    Small Elsevier Logo
    RELX Group